Therapeutic Options for Old World Cutaneous Leishmaniasis and New World Cutaneous and Mucocutaneous Leishmaniasis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Drugs

• Publication date

  2013-10-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40265-013-0132-1PMID 24170665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cutaneous Leishmaniasis

  2020cited by this paper
• Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers.

  2013cited by this paper
• Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis.

  2013cited by this paper
• Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.

  2013cited by this paper
• Leishmaniasis Worldwide and Global Estimates of Its Incidence

  2012cited by this paper
• Is topical nitric oxide and cryotherapy more effective than cryotherapy in the treatment of old world cutaneous leishmaniasis?

  2012cited by this paper
• Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.

  2012cited by this paper
• Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.

  2012cited by this paper
• Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.

  2012cited by this paper
• A pilot study comparing low‐dose liposomal amphotericin B with N‐methyl glucamine for the treatment of American cutaneous leishmaniasis

  2012cited by this paper
• Successful Treatment of Old World Cutaneous Leishmaniasis Caused by Leishmania infantum with Posaconazole

  2011cited by this paper
• Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults.

  2011cited by this paper
• Treatment of imported New World cutaneous leishmaniasis in Germany

  2011cited by this paper
• Efficacy of CO2 laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate

  2011cited by this paper
• Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.

  2011cited by this paper
• Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine

  2011cited by this paper
• Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial.

  2011cited by this paper
• Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?

  2011cited by this paper
• Liquid nitrogen cryotherapy on Leishmania donovani cutaneous leishmaniasis

  2011cited by this paper
• A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis.

  2011cited by this paper
• Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica

  2011cited by this paper
• Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.

  2010cited by this paper
• Successful treatment of childhood cutaneous leishmaniasis with liposomal amphotericin B: report of two cases.

  2010cited by this paper
• Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis.

  2010cited by this paper
• Control of the leishmaniases.

  2010cited by this paper
• Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled Trial

  2010cited by this paper
• A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis.

  2010cited by this paper
• Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study

  2010cited by this paper
• Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani

  2010cited by this paper
• Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment.

  2010cited by this paper
• Efficacy of short‐duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous leishmaniasis in India

  2010cited by this paper
• A Randomized Controlled Trial of Local Heat Therapy Versus Intravenous Sodium Stibogluconate for the Treatment of Cutaneous Leishmania major Infection

  2010cited by this paper
• Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia.

  2009cited by this paper
• Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil

  2009cited by this paper
• WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind, Placebo Controlled Study

  2009cited by this paper
• Low Plasma Membrane Expression of the Miltefosine Transport Complex Renders Leishmania braziliensis Refractory to the Drug

  2009cited by this paper
• Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis

  2009cited by this paper
• The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting.

  2009cited by this paper
• Leishmaniasis due to L. infantum presenting as macrocheilitis and responding to liposomal amphotericin B.

  2009cited by this paper
• Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines.

  2009cited by this paper
• Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.

  2009cited by this paper
• Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine

  2008cited by this paper
• Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan.

  2008cited by this paper
• Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.

  2008cited by this paper
• Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.

  2008cited by this paper
• Cutaneous leishmaniasis – Authors' reply

  2008cited by this paper
• Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis.

  2008cited by this paper
• Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis.

  2007cited by this paper
• Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.

  2007cited by this paper
• Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.

  2007cited by this paper
• Cutaneous leishmaniasis.

  2007cited by this paper
• Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis.

  2007cited by this paper
• Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B.

  2007cited by this paper
• An Australian case of New World cutaneous leishmaniasis

  2007cited by this paper
• Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.

  2007cited by this paper
• Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses

  2007cited by this paper
• Treatment of Bolivian mucosal leishmaniasis with miltefosine.

  2007cited by this paper
• First case of typical Old World cutaneous leishmaniasis treated with miltefosine

  2007cited by this paper
• Cutaneous leishmaniasis treatment.

  2007cited by this paper
• Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate

  2007cited by this paper
• [Adverse effects of intralesional Glucantime in the treatment of cutaneous leishmaniosis].

  2006cited by this paper
• Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis

  2006cited by this paper
• Treatment of New World cutaneous leishmaniasis with miltefosine.

  2006cited by this paper
• Les effets indésirables du Glucantime® en intralésionnel dans le traitement de la leishmaniose cutanée

  2006cited by this paper
• Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis

  2006cited by this paper
• Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report

  2006cited by this paper
• Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.

  2006cited by this paper
• Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo‐controlled, randomized clinical trial

  2006cited by this paper
• Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.

  2006cited by this paper
• [Management of cutaneous leishmaniasis in adults and children].

  2005cited by this paper
• Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran

  2005cited by this paper
• Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B.

  2005cited by this paper
• Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.

  2005cited by this paper
• Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis.

  2005cited by this paper
• Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis

  2005cited by this paper
• A randomized, double‐blind, placebo‐controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis

  2005cited by this paper
• Treatment of cutaneous leishmaniasis with cryosurgery

  2005cited by this paper
• Cutaneous leishmaniasis in Afghani refugees

  2005cited by this paper
• Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial.

  2005cited by this paper
• Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.

  2005cited by this paper
• Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.

  2005cited by this paper
• Miltefosine for new world cutaneous leishmaniasis.

  2004cited by this paper
• Azithromycin in the treatment of mucosal leishmaniasis.

  2004cited by this paper
• CLINICAL FEATURES, EPIDEMIOLOGY, AND EFFICACY AND SAFETY OF INTRALESIONAL ANTIMONY TREATMENT OF CUTANEOUS LEISHMANIASIS: RECENT EXPERIENCE IN TURKEY

  2004cited by this paper
• Challenges and new discoveries in the treatment of leishmaniasis

  2004cited by this paper
• Evaluation of CO2 laser efficacy in the treatment of cutaneous leishmaniasis

  2004cited by this paper
• Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.

  2004cited by this paper
• Disseminated cutaneous leishmaniasis.

  2004cited by this paper
• Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime®) alone for the treatment of cutaneous leishmaniasis

  2004cited by this paper
• Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.

  2004cited by this paper
• Itraconazole in the treatment of New World mucocutaneous leishmaniasis

  2004cited by this paper
• Evaluation of CO laser efficacy in the treatment of cutaneous leishmaniasis.

  2004cited by this paper
• Efficacy of azithromycin in the treatment of cutaneous leishmaniasis.

  2003cited by this paper
• Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate

  2003cited by this paper
• [A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV/day for 20 days to treat cutaneous leishmaniasis].

  2003cited by this paper
• The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis

  2003cited by this paper
• Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-99.

  2003cited by this paper
• [Liposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniate].

  2003cited by this paper
• Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran.

  2003cited by this paper
• Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam

  2002cited by this paper

• Investigation of Viscoelastic Properties of Macrophage Membrane–Cytoskeleton Induced by Gold Nanorods in Leishmania Infection

  2025cites this paper
• Nanofibrous patches for targeted therapy of cutaneous leishmaniasis caused by Leishmania major: a preclinical amphotericin B platform

  2025cites this paper
• Recent advances in the genetic engineering of the Leishmania parasite and anti-cancer properties

  2025cites this paper
• Cutaneous and Mucocutaneous Leishmaniasis: Perspectives on Immunity, Virulence, and Treatment

  2025cites this paper
• Comparative Efficacy of Intralesional Chloroquine With Intralesional Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

  2024cites this paper
• In vitro evaluation of antileishmanial activity of Boswellia serrata essential oil nanoliposome

  2024cites this paper
• Involving patients in drug development for Neglected Tropical Diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development

  2024cites this paper
• The Novel Treatments Based on Tissue Engineering, Cell Therapy and Nanotechnology for Cutaneous Leishmaniasis.

  2023cites this paper
• Cutaneous Leishmaniasis: Physiopathology, Molecular Diagnostic, and Therapeutic Approaches

  2023cites this paper
• Impetiginous Cutaneous Leishmaniasis after COVID-19 Infection in a Patient with Poor Cardiac Profile: A Case Report and Literature Review

  2023cites this paper
• Efficacy of fibroblast transplantation in the healing of cutaneous leishmaniasis scar: A case report

  2023cites this paper
• Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis

  2022cites this paper
• Kutane Leishmaniose nach Urlaub auf Mallorca

  2022cites this paper
• Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review

  2022cites this paper
• A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World

  2022cites this paper
• Establish an allele-specific real-time PCR for Leishmania species identification

  2022cites this paper
• A family cluster of cutaneous Leishmania major infection unresponsive to intralesional meglumine antimonial: Case reports.

  2022cites this paper
• Therapeutic effects of Lucilia sericata larval excretion/secretion products on Leishmania major under in vitro and in vivo conditions

  2022cites this paper
• Single nucleotide polymorphisms in genes involved in immune responses and outcome of tegumentary leishmaniasis.

  2022cites this paper
• Topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis caused by Leishmania major: a double‐blind, randomized, placebo‐controlled, pilot study

  2022cites this paper
• Systemic Drugs Used to Treat American Tegumentary Leishmaniasis

  2022cites this paper
• Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B

  2021cites this paper
• Cutaneous and Mucocutaneous Leishmaniasis.

  2021cites this paper
• Cutaneous and Mucocutaneous Leishmaniasis.

  2021cites this paper
• Cutaneous leishmaniasis after a vacation in Mallorca

  2021cites this paper
• Immunotherapeutic effects of Glycyrrhiza glabra and Glycyrrhizic Acid on Leishmania major‐infection BALB/C mice

  2021cites this paper
• A Novel Drug Delivery System for Amphotericin B to Treat Cutaneous Leishmaniasis

  2021cites this paper
• Comparative assessment of interventions for treating cutaneous leishmaniasis: A network meta-analysis of randomized clinical trials.

  2021cites this paper
• In Vitro Antileishmanial Effects of Saffron Compounds, Crocin and Stigmasterol, on Iranian Strain of Leishmania major (MHOM/IR/75/ER)

  2021influential citation
• The therapeutic effects of larval excretion/secretion of Lucilia sericata on Leishmania major under in vitro and in vivo conditions

  2021cites this paper
• Macrophage metallothioneins participate in the antileishmanial activity of antimonials

  2020cites this paper
• Macrophage supernatant infected with Leishmania major mediates the cytology of fibroblast cells in skin wounds

  2020cites this paper
• Efficacy of combined parenteral meglumine antimoniate and oral allopurinol with meglumine antimoniate alone in treatment of cutaneous leishmaniasis

  2020cites this paper
• Domestic Mammals as Reservoirs for Leishmania donovani on the Indian Subcontinent: Possibility and Consequences on Elimination.

  2020cites this paper
• Safety profile of meglumine antimoniate intralesional infiltration for cutaneous leishmaniasis

  2020cites this paper
• Patients’ preferences of cutaneous leishmaniasis treatment outcomes: Findings from an international qualitative study

  2020cites this paper
• In Vitro Anti-Leishmanial Effect of Metallic Meso-Substituted Porphyrin Derivatives against Leishmania braziliensis and Leishmania panamensis Promastigotes Properties

  2020cites this paper
• Antileishmanial drugs activate inflammatory signaling pathways via toll-like receptors (docking approach) from Leishmania amazonensis-infected macrophages.

  2020cites this paper
• Butanol Fraction of Kelussia odoratissima Mozaff Inhibits the Growth of Leishmania major Promastigote and Amastigote

  2020cites this paper
• Using Q-methodology to understand the perspectives and practical experiences of dermatologists about treatment difficulties of cutaneous leishmaniasis

  2020cites this paper
• Leishmanicidal therapy targeted to parasite proteases

  2019cites this paper
• Research Progress of [68Ga]Citrate PET’s Utility in Infection and Inflammation Imaging: a Review

  2019cites this paper
• DNA Topoisomerases of Leishmania parasites; druggable targets for drug discovery.

  2019cites this paper
• Chitosan-based biocompatible dressing for treatment of recalcitrant lesions of cutaneous leishmaniasis: A pilot clinical study

  2019cites this paper
• Current and emerging medications for the treatment of leishmaniasis

  2019cites this paper
• Comparing the Efficacy of Oral Chloroquine versus Oral Tetracycline in the Treatment of Cutaneous Leishmaniasis.

  2019cites this paper
• The rough journey to access health care : the case of leishmaniasis in the Bolivian rainforest

  2019influential citation
• Impacto de un brote de leishmaniasis en población inmunosuprimida no VIH

  2019cites this paper
• Lip leishmaniasis: evaluation of 20 patients

  2019cites this paper
• Tandem Mass Tag Proteomic Analysis of In vitro and In vivo Models of Cutaneous Leishmaniasis Reveals Parasite-specific and Non-specific Modulation of Proteins in the Host.

  2019cites this paper
• A retrospective study on demographic and clinical characteristics of cutaneous leishmaniasis suspected cases in southern Israel, 2013-2016: Comparison between confirmed and negative cases

  2019cites this paper
• Fractional Ablative CO2 Laser Followed by Topical Application of Sodium Stibogluconate for Treatment of Active Cutaneous Leishmaniasis: A Randomized Controlled Trial.

  2019influential citation
• Synthesis and characterization of radiation cross-linked PVP hydrogels and investigation of its potential as an antileishmanial drug carrier

  2019cites this paper
• Characterisation of the anti-Gal response to Leishmania infection, and its possible exploitation for the diagnosis of cutaneous leishmaniasis

  2019cites this paper
• Efficacy of voriconazole on leishmaniasis by Leishmania major: An in vitro and in vivo study

  2018cites this paper
• Mucosal leishmaniasis: urgent need for more research.

  2018cites this paper
• Dual immune effect of iNKT cells considering human cutaneous and visceral leishmaniasis: An example of cell plasticity according to different disease scenarios

  2018cites this paper
• An international qualitative study exploring patients’ experiences of cutaneous leishmaniasis: study set-up and protocol

  2018cites this paper
• A review of cutaneous leishmaniasis in Morocco: A vertical analysisto determine appropriate interventions for control and prevention.

  2018cites this paper
• Transforming Growth Factor Beta (TGFβ1) and Epidermal Growth Factor (EGF) as Biomarkers of Leishmania (V) braziliensis Infection and Early Therapeutic Response in Cutaneous Leishmaniasis: Studies in Hamsters

  2018cites this paper
• 6,7-Dehydroroyleanone diterpene derived from Tetradenia riparia essential oil modulates IL-4/IL-12 release by macrophages that are infected with Leishmania amazonensis

  2018cites this paper
• Effects of a Traditional Iranian Remedy on Cutaneous Leishmaniasis

  2018cites this paper
• Calophyllum brasiliense Modulates the Immune Response and Promotes Leishmania amazonensis Intracellular Death

  2018cites this paper
• Visceral and Cutaneous Leishmaniasis Recommendations for Solid Organ Transplant Recipients and Donors.

  2018cites this paper
• Fractional ablative carbon dioxide laser followed by topical sodium stibogluconate application: A treatment option for pediatric cutaneous leishmaniasis

  2018cites this paper
• In Vitro Antileishmanial Activity of Falcaria vulgaris Fractions on Leishmania major

  2017cites this paper
• Dermal leishmaniasis in a 25-year-old Syrian refugee

  2017cites this paper
• Lip leishmaniasis: a case series with molecular identification and literature review

  2017cites this paper
• Live Leishmania tarentolae secreting HNP1 as an immunotherapeutic tool against Leishmania infection in BALB/c mice.

  2017cites this paper
• Diagnostic and Therapeutic Aspects of Mucosal Leishmaniasis

  2017cites this paper
• Pharmaco- and immunotherapeutic strategies for the topical treatment of cutaneous leishmaniasis

  2017cites this paper
• White starburst-like pattern as a dermoscopic clue in Old World cutaneous leishmaniasis *

  2017cites this paper
• Cutaneous leishmaniasis and its clinical spectrum. An overview from the Old World

  2017cites this paper
• An overview of skin lesions adapted to Cutaneous Leishmaniasis in Persian Medicine

  2017cites this paper
• Last Decade Developments on Leishmania Vaccines with Emphasis on Nanovaccines

  2017cites this paper
• New evidence of cutaneous leishmaniasis in north‐eastern Italy

  2017cites this paper
• Antileishmanial activity and tubulin polymerization inhibition of podophyllotoxin derivatives on Leishmania infantum

  2017cites this paper
• Interventions for Old World cutaneous leishmaniasis.

  2017cites this paper
• Protozoan Diseases: Leishmaniasis

  2017cites this paper
• Interventions for Old World cutaneous leishmaniasis.

  2017cites this paper
• Nanoarchitectures for Neglected Tropical Protozoal Diseases: Challenges and State of the Art

  2017cites this paper
• Synthetic analogs of an Entamoeba histolytica glycolipid designed to combat intracellular Leishmania infection

  2017cites this paper
• Intralesional Versus Oral Chloroquine in Cutaneous Leishmaniasis: Comparison of Outcome, Duration of Treatment and Total Dose of Drug.

  2016cites this paper
• Cutaneous Leishmaniasis of the Eyelids: A Case Series with Molecular Identification and Literature Review

  2016cites this paper
• The sesquiterpene (−)-α-bisabolol is active against the causative agents of Old World cutaneous leishmaniasis through the induction of mitochondrial-dependent apoptosis

  2016cites this paper
• Leishmaniasis cutánea de inoculación mucosa tratada con miltefosina oral

  2016cites this paper
• Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis: a preliminary report

  2016influential citation
• Antileishmanial and immunomodulatory effects of the essential oil from Tetradenia riparia (Hochstetter) Codd

  2016cites this paper
• Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective

  2016cites this paper
• Topical Treatment of Leishmania tropica Infection Using (-)-α-Bisabolol Ointment in a Hamster Model: Effectiveness and Safety Assessment.

  2016cites this paper
• Nanoparticles in the Topical Treatment of Cutaneous Leishmaniasis: Gaps, Facts, and Perspectives

  2016cites this paper
• Cutaneous leishmaniasis: 20 years' experience in a Spanish tertiary care hospital.

  2015cites this paper
• Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.

  2015cites this paper
• Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB)

  2015cites this paper
• The Dialogue of the Host-Parasite Relationship: Leishmania spp. and Trypanosoma cruzi Infection

  2015cites this paper
• Nanoemulsions containing a synthetic chalcone as an alternative for treating cutaneous leshmaniasis: optimization using a full factorial design

  2015cites this paper
• Leishmaniasis: Epidemiology, Control and Future Perspectives with Special Emphasis on Egypt

  2015cites this paper
• Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.

  2015cites this paper
• An update on pharmacotherapy for leishmaniasis

  2015influential citation
• Conventional formulations and emerging delivery systems for the topical treatment of Cutaneous Leishmaniasis.

  2015cites this paper